IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

This trial is testing IFx-Hu2.0, a new drug injected directly into tumors, combined with the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma — a rare and aggressive skin cancer. **You may be eligible if...** - You are 18 or older - You have confirmed Stage III or IV Merkel cell carcinoma that cannot be surgically removed - You have at least one tumor that can be directly injected and is 3 mm or larger - You have never received any checkpoint immunotherapy (such as pembrolizumab, avelumab, or nivolumab) - Your overall health and organ function meet the required thresholds - Your life expectancy is at least 6 months **You may NOT be eligible if...** - You have previously received checkpoint immunotherapy - You have active autoimmune disease requiring systemic treatment - You have severe organ dysfunction or active serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.